Status:
UNKNOWN
Physiological and Sensory Responses to Prolonged Fasting in Humans
Lead Sponsor:
University of Bath
Collaborating Sponsors:
University of Nottingham
Conditions:
Fasting
Metabolic Disturbance
Eligibility:
All Genders
18-45 years
Phase:
NA
Brief Summary
This study aims to establish the metabolic/molecular response in both adipose tissue and skeletal muscle as well as sensory experiences (pain, fatigue, drive) to prolonged fasting of 3 days duration. ...
Detailed Description
This study will employ a single-arm, non-randomised design in which participants will act as their own control prior to undergoing 3 days of fasting. The control phase includes 3 days of habitual ener...
Eligibility Criteria
Inclusion
- • Body mass index 20.0-29.9 kg∙m-2
- Age 18-45 years
- Willing to abstain from food intake for just over 3 days (\~82 hours)
- Able and willing to provide informed consent and safely comply with study procedures
- Females to maintain record of regular menstrual cycle phase or contraceptive use
- No anticipated changes in lifestyle during the study (e.g. holidays or exercise programmes)
Exclusion
- • Any reported condition or behaviour deemed either to pose undue personal risk to the participant or introduce bias
- Any diagnosed metabolic disease (e.g. type 1 or type 2 diabetes)
- Any reported use of substances which may pose undue personal risk to the participants or introduce bias into the experiment
- Pregnancy
- Breastfeeding
- Lifestyle not conforming to standard sleep-wake cycle (e.g. shift worker)
- History of eating disorders (e.g. anorexia)
- Any reported recent (\<6 months) change in body mass (± 3%)
- Uncontrolled hyperthyroidism
- Advanced cerebrovascular insufficiency or dementia
- Advanced liver or kidney insufficiency
- History of migraine and or headache
- Psychotic disorders
- Unstable or severe coronary artery disease
- Retinal detachment
- Duodenal or stomach ulcer
- Cancer and malignant disease
- Regular use of Non-steroidal anti-inflammatory drugs (NSAIDs)
- Use of Systemic corticoids
- Use of Antihypertensives (especially beta-blockers and diuretics)
- Use of Antidiabetics
- Use of Anti-coagulants
- Use of Psychotropics (especially neuroleptics and lithium)
- Use of Anticonvulsants.
Key Trial Info
Start Date :
June 28 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 30 2024
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT05977569
Start Date
June 28 2021
End Date
May 30 2024
Last Update
August 4 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Bath
Bath, Somerset, United Kingdom, BA2 7AY